01801.HK
Innovent Biologics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 102.40
−0.19%Year over year
Reported trailing growth
- Revenue
- +116.5%
- EBITDA
- +207.0%
- EBIT
- +163.5%
- EPS
- +180.6%
- Free cash flow
- +419.1%
- Operating cash flow
- +1082.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +42.0%
- EBITDA
- +372.8%
- EBIT
- +197.1%
- Net income
- +959.7%
- EPS
- +926.2%
- Free cash flow
- +2327.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026